课题基金 / 基金详情

Phase Ib trial of TD101 siRNA for pachyonychia congenita (IND 77,504, 12-03-07)

Phase Ib trial of TD101 siRNA for pachyonychia congenita (IND 77,504, 12-03-07)
TD101 siRNA 治疗先天性厚甲症的 Ib 期试验(IND 77,504, 12-03-07)
批准号:
7802000
负责人:
SANCY ANN LEACHMAN
金额:
$7.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-20 至 2010-09-19
关键词:

项目摘要

项目成果

SANCY ANN LEACHMAN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): RNA干扰(RNAi)有可能使显性遗传疾病的治疗发生革命性变化。小分子抑制性RNA(SiRNAs)是一种高效、选择性强的单核苷酸特异性分子。使用siRNAs的临床试验目前正在进行中,用于一些适应症,包括年龄相关性黄斑变性和呼吸道合胞病毒感染。目前还没有针对皮肤病的siRNA治疗 到目前为止被引入诊所。这项提议是为了使用TD101进行一项针对先天性厚甲(PC)的临床试验,PC是一种极其罕见的遗传性皮肤病。TD101是一种针对编码角蛋白6a(K6a)基因的单核苷酸突变的siRNA,导致天冬酰胺转变为赖氨酸。PC患者的主要主诉是虚弱、疼痛的老茧和 发生在脚的压力点或其附近的水泡。在拟议的临床试验中,K6a N171K突变携带者脚底的这些指定区域将作为局部siRNA治疗的目标。所有已知的、符合条件的和愿意接受K6a N171K突变的美国患者将在1b期临床试验中接受治疗。这项试验是第一次在皮肤上进行siRNA治疗。 虽然先天性厚甲是一种罕见的疾病,但这种疾病的性质使其成为最初siRNA临床试验的理想皮肤病原型(已定义的突变,在有限的已定义区域表达),所学到的经验应很容易推广到其他皮肤疾病,包括罕见的疾病,如单纯性大疱性表皮松解症。
英文摘要
DESCRIPTION (provided by applicant): RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and selective, demonstrating remarkable single-nucleotide specificity. Clinical trials using siRNAs are currently underway for a few indications including age-related macular degeneration and respiratory syncitial virus infection. No siRNA treatment of skin disorders has been introduced into the clinic to date. This proposal is for a clinical trial for pachyonychia congenita (PC), an ultra-rare genetic skin disorder, using TD101. TD101 is a siRNA that specifically and potently targets a single nucleotide mutation in the gene encoding keratin 6a (K6a), resulting in a pathogenic amino acid change of asparagine to lysine. The major complaint of PC patients is the debilitating, painful callusing and blistering which occurs on or near the pressure points of the feet. It is these defined regions on the soles of the feet of K6a N171K mutation carriers that are targeted for local siRNA treatment in the proposed clinical trial. All known, eligible and willing U.S. patients with the K6a N171K mutation will be treated in a Phase 1b clinical trial. This trial is the "first-in-man" for siRNA treatment in skin. Although pachyonychia congenita is a rare disease, the nature of the disorder makes it an ideal prototype skin disorder (defined mutations with expression in limited, defined areas) for an initial siRNA clinical trial and the lessons learned should be readily generalized to other skin disorders including rare disorders such as epidermolysis bullosa simplex.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
17th Annual Meeting of the PanAmerican Society of Pigment Cell Research
  • 批准号:
    8400005
  • 项目类别:
  • 资助金额:
    $2.5万
  • 财政年份:
    2012
  • 负责人:
    SANCY ANN LEACHMAN
  • 依托单位:
Phase Ib trial of TD101 siRNA for pachyonychia congenita (IND 77,504, 12-03-07)
  • 批准号:
    7558901
  • 项目类别:
  • 资助金额:
    $10.16万
  • 财政年份:
    2008
  • 负责人:
    SANCY ANN LEACHMAN
  • 依托单位:
FAMILIAL MELANOMA RESEARCH CLINIC (FMRC)
  • 批准号:
    7718485
  • 项目类别:
  • 资助金额:
    $1.1万
  • 财政年份:
    2008
  • 负责人:
    SANCY ANN LEACHMAN
  • 依托单位:
FAMILIAL MELANOMA RESEARCH CLINIC (FMRC)
  • 批准号:
    7604943
  • 项目类别:
  • 资助金额:
    $7.01万
  • 财政年份:
    2007
  • 负责人:
    SANCY ANN LEACHMAN
  • 依托单位:
国内基金
海外基金
基于IB-GHPC方法的开孔结构物非线性水动力学特性及机理研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
一项评估胰腺癌新型免疫治疗的Ib/II期平台型临床研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    施思
  • 依托单位:
替雷利珠单抗联合短程放化疗转化治疗食管鳞癌的Ib期临床研究
MHC Ib 限制性 CD8+T 细胞抗肿瘤免疫应答的机制与应用策略